Dr. Alexander P. Boardman, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Massachusetts Medical School (2017)
- Years since graduation
- 9
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 119
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2017Medical school: University of Massachusetts Medical School
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 304080
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Hematology Lymphoma Group (216 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 119
- Services billed
- 405
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 98 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 35 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 27 | 19 |
| Hospital discharge day management, more than 30 minutes | 19 | 18 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in New York, NY | 101 |
| Prednisone Other prescribers in New York, NY | 39 |
| Pantoprazole Sodium Other prescribers in New York, NY | 36 |
| Brukinsa (zanubrutinib) | 33 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in New York, NY | 27 |
| Entecavir | 22 |
| Amlodipine Besylate Other prescribers in New York, NY | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 16 payments worth $31,718 in total to this clinician.
| Celgene Corporation | $15,677 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $9,240 |
| Incyte Corporation | $6,625 |
| Genmab U.S., Inc. | $121 |
| Epizyme, Inc. | $55.00 |
| Travel and Lodging | $16,444 |
|---|---|
| Consulting Fee | $9,230 |
| Compensation for services other than consulting (speaking, faculty) | $5,500 |
| Food and Beverage | $444 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Celgene Corporation May 16, 2025 | Travel and Lodging travel to Munich, Germany | $15,314 |
| E.r. Squibb & Sons, L.l.c. May 29, 2025 | Consulting Fee | $9,230 |
| Incyte Corporation Aug 27, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $2,200 |
| Incyte Corporation Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,650 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,375 |
| Incyte Corporation Aug 19, 2025 | Travel and Lodging Monjuvi · Oncology · travel to New York, NY | $458 |
| Incyte Corporation Aug 20, 2025 | Travel and Lodging Monjuvi · Oncology · travel to Tampa, FL | $427 |
| Incyte Corporation May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $275 |
| Celgene Corporation May 15, 2025 | Travel and Lodging travel to Munich, Germany | $245 |
| Incyte Corporation Sep 17, 2025 | Education | $99.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $31,658 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.